[Angiogenesis inhibitors and radiation therapy: from biology to clinical practice]

R Mazeron; D Azria; E Deutsch

doi:10.1016/j.canrad.2009.06.015

[Angiogenesis inhibitors and radiation therapy: from biology to clinical practice]

Cancer Radiother. 2009 Oct;13(6-7):568-73. doi: 10.1016/j.canrad.2009.06.015. Epub 2009 Aug 19.

[Article in French]

Authors

R Mazeron¹, D Azria, E Deutsch

Affiliation

¹ Département de Radiothérapie, Institut Gustave-Roussy, 94805 Villejuif, France.

PMID: 19695932
DOI: 10.1016/j.canrad.2009.06.015

Abstract

Angiogenesis is central to cancer research. Recent progresses in understanding its mechanisms have enabled the development of therapies that inhibit this process. Many molecules have shown a synergistic effect in combination with irradiation in preclinical studies, and several are being tested in phase I or II. This effect could be explained by a transient normalization of tumor vasculature, leading to improve tumor oxygenation and thus greater radiosensitivity. Although promising, many questions remain about the dose, optimal sequences of the association.

Publication types

English Abstract
Review

MeSH terms

Angiogenesis Inhibitors / therapeutic use*
Clinical Trials as Topic
Combined Modality Therapy
Fibroblast Growth Factor 2 / antagonists & inhibitors
Humans
Neoplasms / blood supply*
Neoplasms / radiotherapy*
Neoplastic Stem Cells / drug effects
Neoplastic Stem Cells / physiology
Neoplastic Stem Cells / radiation effects
Radiation Tolerance / drug effects
Radiation Tolerance / physiology
Radiotherapy / methods*
Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

Angiogenesis Inhibitors
Vascular Endothelial Growth Factor A
Fibroblast Growth Factor 2